【スタッフ紹介】金廣 有彦

【卒業年】1984年

【学位取得年月】1992年

【専門領域】
呼吸器・アレルギー内科学

【資格等】
麻酔科標榜医, 日本内科学会認定医, 日本内科学会指導医, 日本アレルギー学会専門医, 日本アレルギー学会指導医, インフェクションコントロールドクター, 日本アレルギー学会代議員, 日本呼吸器学会代議員, 日本呼吸ケア・リハビリテーション学会代議員, 日本内科学会中国地方会評議員, 日本肺癌学会・日本呼吸器学会中国四国地方会合同幹事会幹事, 日本呼吸器学会中国四国地方会評議員, 日本アレルギー学会国際交流委員会委員, 日本呼吸器学会アレルギー・免疫・炎症学術部会将来計画委員, 日本内科学会支部生涯教育事業ワーキング委員, 「喘息予防・管理ガイドライン2015」作成委員

【所属学会等】
日本内科学会, 日本アレルギー学会, 日本呼吸器学会, 日本免疫学会, 日本呼吸器内視鏡学会, 日本感染症学会, 日本肺癌学会, 日本職業・環境アレルギー学会, 日本呼吸ケア・リハビリテーション学会, American Thoracic Society(ATS), European Respiratory Society(ERS), 国際喘息学会(Interasthma), 岡山アレルギーを考える会代表世話人, 岡山岡南胸部疾患フォーラム代表世話人, 岡山呼吸器疾患研究会世話人, 岡山びまん性肺疾患研究会世話人, 岡山吸入療法研究会世話人, 中国・四国喘息研究フォーラム世話人, 岡山重症喘息治療研究会世話人

【略歴】
1984年 岡山大学医学部麻酔科
1985年 呉共済病院麻酔科
1986年 岡山大学医学部第二内科
1986年 坂出市立病院内科
1987年 中国中央病院内科医長
1888年 広島マツダ病院内科医長
1989年 岡山大学医学部第二内科
1992年 岡山大学医学部第二内科(現 血液・腫瘍・呼吸器・アレルギー内科)助手
2005年 岡山大学病院血液・腫瘍・呼吸器・アレルギー内科 講師
2011年 岡山大学大学院医歯薬学総合研究科 血液・腫瘍・呼吸器・アレルギー内科学 准教授
現在に至る
1997−2000 National Jewish Medical and Research Center (現National Jewish Health). Denver, Colorado, USA.

【一言】
医療を含めすべてにおいて「一期一会」を大切にしています.
何時でもご連絡をお待ちしております. 一緒にがんばりましょう.

【研究テーマ】
気管支喘息及びCOPDの機序の解明と新規治療薬の開発

【特許】
1. US 6737398, EP 1229790, WO 0122816
“Modulation of  T cells to regulate airway hyperresponsiveness”
2. US 7563768, GB2414395, CA2519921, WO 2004084934
“A preventive or therapeutic agent for asthma, comprising HGF or its salt as an active ingredient”

【主な業績】

1) Negative regulation of airway responsiveness that is dependent on gammadelta T cells and independent of alphabeta T cells. Nature Med 5:1150-6. 1999.

2) The failure of STAT6-deficient mice to develop airway eosinophilia and airway hyperresponsiveness is overcome by interleukin-5. Am J Respir Crit Care Med 160:1283-1291. 1999.

3) Role of gammadelta T cells in protecting normal airway function. Respir Res 1:151-158, 2000.

4) IL-10 is necessary for the expression of airway hyperresponsiveness but not pulmonary inflammation after allergic sensitization. Proc Natl Acad Sci USA 97:6007-6012. 2000.

5) Type 4 phosphodiesterase inhibitors attenuate respiratory syncytial virus-induced airway hyper-responsiveness and lung eosinophilia. J Pharmacol Exp Ther 294:701-706. 2000.

6) Timing of administration of anti-VLA-4 differentiates airway hyperresponsiveness in the central and peripheral airways in mice. Am J Respir Crit Care Med 162:1132-1139. 2000.

7) Inhibition of phosphodiesterase 4 attenuates airway hyperresponsiveness and airway inflammation in a model of secondary allergen challenge. Am J Respir Crit Care Med 163:173-184. 2001.

8) Low dose exogenous IL-12 enhances antigen-induced IFN-g production without affecting IL-10 production in asthmatics. Allergol Int 50:143-151. 2001.

9) Tumor necrosis factor (TNF)-a negatively regulates airway hyperresponsiveness through gd T cells. Am J Respir Crit Care Med 164:2229-2238. 2001.

10) Gammadelta T cells as regulators of airway hyperresponsiveness. Int Arch Allergy Immunol 125:203-210. 2001.

11) The failure of interleukin-10-deficient mice to develop airway hyperresponsiveness is overcome by respiratory syncytial virus infection in allergen-sensitized/challenged mice. Am J Respir Crit Care Med 165:824-831. 2002.

12) Regulation of Airway Hyperresponsiveness by Calcitonin Gene-related Peptide in Allergen Sensitized and Challenged Mice. Am J Respir Crit Care Med 165:1137-1144. 2002.

13) MHC-Class-I-dependent Vg4+ pulmonary T cells regulate ab T cell-independent airway responsiveness. Proc Natl Acad Sci USA 99:8850-8855. 2002.

14) Fexofenadine modulates T-cell function, preventing allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 110:85-95. 2002.

15) Requirment for the p75 TNF-a receptor (TNFR2) in the regulation of airway hyperresponsiveness by gd T cells. J Immunol 169:4190-4197. 2002.

16) Effects of fexofenadine on T-cell function in a murine model of allergen-induced airway inflammation and hyperresponsiveness. J Allergy Clin Immunol 112:89-95. 2003.

17) Aerosolized anti-T-cell-receptor antibodies are effective against airway inflammation and hyperreactivity. Int Arch Allergy Immunol 134:49-55. 2004.

18) Alteration of airway sensory neuropeptide expression and development of airway hyperresponsiveness following respiratory syncytial virus infection. Am J Physiol Lung Cell Mol Physiol 288:L761-770. 2005

19) Hepatocyte growth factor attenuates airway hyperresponsiveness, inflammation and remodeling. Am J Respir Cell Mol Biol 32:268-280. 2005.

20) Airway Hyperresponsiveness in the Absence of CD4+ T Cells After Primary but not Secondary Challenge. Am J Respir Cell Mol Biol 33:89-96. 2005.

21) Successful treatment of pulmonary artery sarcoma by a two-drug combination chemotherapy consisting of ifosfamide and epirubicin Jpn J Clin Oncol 35:417-419. 2005.

22) Sarcoidosis occurring after interferon-alpha therapy for chronic hepatitis C: report of two cases. Respirology 10:529-534. 2005.

23) Systemic tumor embolism mimicking gefitinib (‘IRESSA’)-induced interstitial lung disease in a patient with lung cancer. Intern Med 44:979-982. 2005.

24) Interstitial lung disease in Japanese patients with non-small cell lung cancer receiving gefitinib: an analysis of risk factors and treatment outcomes in Okayama Lung Cancer Study Group. Cancer J 11:417-424. 2005.

25) Pirfenidone Modulates Airway Responsiveness, Inflammation and Remodeling After Repeated Challenge. Am J Respir Cell Mol Biol 35:366-377. 2006.

26) Severe interstitial pneumonia induced by paclitaxel in a patient with adenocarcinoma of the lung. Acta Med Okayama 60:295-298. 2006.

27) Whole blood interferon-gamma assay for baseline tuberculosis screening among Japanese healthcare students. PLoS ONE 2:e803. 2007.

28) Elevated serum level of sialylated glycoprotein KL-6 predicts a poor prognosis in patients with non-small cell lung cancer treated with gefitinib. Lung Cancer 59:81-87. 2007.

29) Hepatocyte growth factor attenuates eotaxin and PGD2-induced chemotaxis of human eosinophils. Allergy 62: 415-420. 2007.

30) Growth factors temporally associate with airway responsiveness and inflammation in allergen-exposed mice. Int Arch Allergy Immunol 145:324-339. 2007.

31) Inflammatory markers in exhaled breath condensate from patients with asthma. Respirology 5:654-663. 2008.

32) Anti-Allergic Inflammatory Effects of Hepatocyte Growth Factor. Int Arch Allergy Immunol 146:82-87. 2008.

33) Hepatocyte growth factor suppresses production of reactive oxygen species and release of eosinophil-derived neurotoxin from human eosinophils. Int Arch Allergy Immunol 147:331-337. 2008.

34) Quantitative analysis of propionibacterial DNA in bronchoalveolar lavage cells from patients with sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 5:15-20. 2008.

35) Diffuse alveolar hemorrhage with chronic thyroiditis in an advanced-age adult. Respiratory Medicine CEM:1-3. 2009.

36) Experimental pulmonary granuloma mimicking sarcoidosis induced by Propionibacterium acnes in mice. Acta Med Okayama 64:75-83. 2010.

37) Interstitial lung disease during trimethoprim/sulfamethoxazole administration. Acta Med Okayama 64:181-187. 2010.

38) Churg-Strauss syndrome with necrosis of the toe tips. Acta Med Okayama 65: 215-218. 2011.

39) Blocking the leukotriene B4 receptor 1 inhibits late asthmatic responses in establish disease. Am J Respir Cell Mol Biol 45:851-857. 2011.

40) Successful Extracorporeal Life Support for Life-threatening Hypercapnia with Bronchiolitis Obliterans after Allogeneic Hematopoietic Stem Cell Transplantation. Acta Med Okayama 65:403-406. 2011.

41) Requirement for CCR5 in the development of allergen-induced airway hyperresponsiveness and inflammation. Am J Respir Cell Mol Biol 45:1248-1255. 2011.

42) IL-17A is essential to the development of elastase-induced pulmonary inflammation and emphysema in mice. Respir Res 14:5. 2013.

43) Inhibition of neutrophil elastase attenuates airway hyperresponsiveness and inflammation in a mouse model of secondary allergen challenge: neutrophil elastase inhibition attenuates allergic airway responses. Respir Res 14:8. 2013.

44) Effect of fudosteine, a cysteine derivative, on airway hyperresponsiveness, inflammation, and remodeling in a murine model of asthma. Life Sci 2013.

45) Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema. Am J Respir Cell Mol Biol 50:18-29. 2014.

46) Lavender essential oil inhalation suppresses allergic airway inflammation and mucous cell hyperplasia in a murine model of asthma. Life Sci 108:109-115. 2014.

47) Invasive mucinous adenocarcinoma mimicking organizing pneumonia associated with Mycobacterium fortuitum infection. Intern Med 53:2795-2799. 2014.

48) Emphysema requires the receptor for advanced glycation end products triggering on structural cells. Am J Respir Cell Mol Biol 52:482-491. 2015.

戻る

コメントは受け付けていません。